Archives
-
o2h Ventures Wins Best EIS Investment Manager – Specialist at Growth Investor Awards 2024
01 December, 2024
-
o2h Ventures Portfolio Company ViaNautis Enters Strategic Collaboration Agreement with Eli Lilly to Accelerate Genetic Medicine Development
30 October, 2024
-
o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024
09 August, 2024
-
Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS)
06 August, 2024
-
o2h Ventures Proud to be Shortlisted for the EISA Impact Award for a Second Year Running!
07 June, 2024
-
o2h Ventures Announces Seed Investment in AscendBio, A Company Advancing Therapies for Metabolic and Respiratory Diseases
03 May, 2024
-
o2h Ventures Invests in Vesynta, a Company Developing an AI Software to Maximise Therapeutic Potential and De-risk drug development
23 April, 2024
-
o2h Ventures invests in ClotProtect, a Company Developing Treatment to Improve Bleeding and Survival Outcomes
22 April, 2024
-
o2h Ventures Invests in Stratosvir – Advancing Viral Immunotherapy For Late-Stage Cancer
17 April, 2024